ProQR Therapeutics N.V.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
Business Address
ZERNIKEDREEF 9, LEIDEN, P7, 2333 CK
Mailing Address
ZERNIKEDREEF 9, LEIDEN, P7, 2333 CK
Phone
31 88 166 7000
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 8, 2026 | View on SEC |
| 6-K Foreign company current report | April 8, 2026 | View on SEC |
| 6-K Foreign company current report | March 25, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
March 12, 2026
- Strategic expansion into new therapeutic areas (Rett Syndrome) with advanced genetic therapies, diversifying beyond ocular diseases.
- Secured significant capital through an underwritten public offering in October 2024 and holds a shelf registration for future funding flexibility through 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.